With genotyping data for more than 100,000 endometrial cancer cases and controls, researchers found nine new risk loci before delving into genes and pathways involved.
Results of the study, published in JAMA, highlight ongoing and future challenges in translating the promise of comprehensive genomics into clinical benefit.
The disagreement began when NuGen filed a lawsuit seeking a ruling of non-infringement of two of KeyGene's US patents related to next-generation sequencing.
The company said the funds will be used to expand its management team and complete commercialization of its mass spec multinozzle emitter array technology.
Harvard Medical School's Seth Cassel and Cigall Kadoch argue in a Baltimore Sun op-ed that the recent TAILORx trial shows the potential of genomic-based medicine.
Before beginning a large animal study, it is critical to confirm that your labeled targeting agent is specific to the intended target within the biological complexity of the whole animal. Understanding the biodistribution and clearance of a labeled targeting agent is critical for meaningful image analysis and interpretation. This guide will provide an overview of how to validate a targeting agent in vivo.
Tissue section imaging and microscopy are effective for granular identification of targeting agent locations within an organ. With appropriate microscopy equipment, you can assess NIR-labeled targeting agent location (e.g. membrane bound, intracellular, or interstitial).
However, most microscopes are not configured for NIR fluorescence detection. If you're ready to try IRDye® Infrared Dyes on an epifluorescence microscope, this list of microscope requirements will help you get started.
The BD Rhapsody Single-Cell Analysis System empowers and streamlines single-cell research with a complete system of tools, including reagents and analysis software, that work together to meet neuroscience experimental needs. Neuroscientists’ ability to identify and characterize individual cells in the nervous system opens the door to finding pathogenic cells, regenerative cells, and pathways that drug manufacturers can exploit for the discovery of therapeutics for neurodegenerative disease.
